Market Overview

Teva Offers Most Attractive Risk-Reward Profile, Citigroup Says

Related TEVA
Don't Worry Spec. Pharma Investors, Drug Pricing Legislation Probably Won't Affect You
Benzinga's M&A Chatter for Thursday October 1, 2015
The Passive DGI Portfolio: Portfolio Update #4 (Seeking Alpha)

Shares of Teva Pharmaceutical Industries (NYSE: TEVA) are trading higher 1.5 percent to $49.86 after Citigroup added the stock to the U.S. focus list and raised the price target to $60 from $56.

Analyst Liav Abraham believes the shares offer the “most attractive risk-reward profile amongst multinational generics universe.”

The “resilience” of Teva's Copaxone, “commercial potential of the pipeline (particularly the respiratory and NTE portfolio), and optionality for increased net cost savings, as sufficient to drive further upside from current levels,” said Abraham.

The analyst's investment thesis is “not predicated on the need for M&A.”

Abrahams $60 price target is based on a “2015e earnings multiple of 13x, vs the peer group average of 13.6x.”

Latest Ratings for TEVA

Sep 2015NomuraInitiates Coverage onNeutral
Aug 2015Goldman SachsReinstatesBuy
Aug 2015JP MorganUpgradesNeutralOverweight

View More Analyst Ratings for TEVA
View the Latest Analyst Ratings

Posted-In: Citigroup Liav AbrahamAnalyst Color Analyst Ratings


Related Articles (TEVA)

View Comments and Join the Discussion!

Get Benzinga's Newsletters